Principal Financial Group
LRMR icon

Principal Financial Group’s Larimar Therapeutics LRMR Stock Holding History

Principal Financial Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,274
Closed -$2.02M – 2207
2015
Q3 		$2.02M Buy
5,274
+96
+2% +$43.3K ﹤0.01% 1645
2015
Q2 		$2.15M Buy
5,178
+478
+10% +$200K ﹤0.01% 1671
2015
Q1 		$2.23M Sell
4,700
-3,442
-42% -$1.63M ﹤0.01% 1633
2014
Q4 		$3.01M Buy
+8,142
New +$2.1M ﹤0.01% 1586

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Principal Financial Group's LRMR Position: Q4 2015 in Review

Principal Financial Group sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 5,274 shares — an estimated $2.02M sold.

Principal Financial Group first reported a position in LRMR in Q4 2014 and held it in 4 quarters. The position peaked at $3.01M in Q4 2014. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Principal Financial Group reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Principal Financial Group sold 5,274 Larimar Therapeutics shares in Q4 2015, an estimated $2.02M.
  • Principal Financial Group first reported a position in Larimar Therapeutics in Q4 2014 and held it in 4 quarters.
  • Principal Financial Group's Larimar Therapeutics position peaked at $3.01M in Q4 2014.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Principal Financial Group's 13F filing for Q4 2015, filed 9 Feb 2016.